Imprint cytologic features of pulmonary large cell neuroendocrine carcinoma: Comparison with classic large cell carcinoma

2004 ◽  
Author(s):  
Akira Iyoda ◽  
Masayuki Baba ◽  
Kenzo Hiroshima ◽  
Hiroko Saitoh ◽  
Yasumitsu Moriya ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma

scholarly journals Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma

2022 ◽  
Vol 11 ◽  
Author(s):  
Ying Chen ◽  
Xiaoying Cui ◽  
Di Wang ◽  
Guojie Xia ◽  
Minyan Xing ◽  
...  
Keyword(s):  
Survival Analysis ◽  
Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Gene Panel ◽  
Smoking History ◽  
Study Cohort ◽  
Poor Outcome

PurposeLarge cell neuroendocrine carcinoma (LCNEC) and classic large cell carcinoma (LCC) are two distinct entities with different histological and biological characteristics. However, the mutational profiles and the clinical behavior of the two subtypes of lung cancer remain to be explored.Patients and MethodsPathological diagnoses of all screened patients were finally confirmed by three or four experienced pathologists. Patients with uncertain pathological diagnoses were excluded. Finally, we genetically profiled ten patients with LCNEC and seven with LCC. ALL patients were subjected to next-generation sequencing (NGS) test, which included nine patients sequenced with a 139-gene panel and eight patients with a 425-gene panel. Including only intersected mutations from these two panels, survival analysis was further conducted.ResultsBoth LCNEC and LCC showed high prevalence in male patients, with no clear association with smoking history. Potential targetable mutations in KRAS and RET were detected in the study cohort. However, LCNEC and LCC showed distinct mutational profiles with an enrichment of RB1/TP53 co-mutations in a subset of LCNEC patients. SMARCA4 and KEAP1 mutations were exclusively found in LCC patients, and RICTOR, BRAF, ROS1 and TET2 mutations were only detected in LCNEC. LCC patients in the cohort had shorter survival compared to LCNEC patients (p=0.006). Survival analysis revealed an association between SMARCA4 mutations and poor outcome in the study cohort and in the LCC subset. Mutations in BRAF were associated with a trend of increased survival in the study cohort, as well as in the LCNEC subset. Finally, TET2 mutations were associated with poor outcome in the LCNEC cohort.ConclusionLCC and LCNEC were both heterogeneous diseases with limited treatment options. Our study identified potential targetable mutations and prognostic biomarkers that might provide more therapeutic options and improve individualized patient care.

scholarly journals Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology

Cancer ◽  
2001 ◽  
Vol 91 (11) ◽  
pp. 1992-2000 ◽  
Author(s):  
Akira Iyoda ◽  
Kenzo Hiroshima ◽  
Tetsuya Toyozaki ◽  
Yukiko Haga ◽  
Takehiko Fujisawa ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma
Sign in / Sign up

Export Citation Format

Share Document